搜索此博客

2018年3月5日星期一

Impurity List


EOS Med ChemMedchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
2018. 4.18 Japan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend


住所: Diaozhen Chemical Industrial Park, Jinan City, China





Alfuzosin EP Impurity B
2-chloro-6,7-dimethoxyquina zolin-4-amine / 4-Amino-2- chloro- 6,7-dimethoxy quinazoline
Alfuzosin EP Impurity F

N-(3-(((4-amino-6, 7-dihydro xyquinazolin-2-yl) methyl) (methyl) amino) propyl) tetrahydrofuran-2- carboxamide
Colsevelam Impurities


Aziobis (Colsevelam impurity- 7)

2,2-azobis(2- amidinopropane) dihydrochloride
Lidocaine Impurities

Lidocaine BP Impurity B / Lidocaine N-Oxide


2-(Diethylazinoyl)-N-(2,6- dimethylphenyl)acetamide


Lidocaine BP Impurity H


2-Chloro-N-(2,6- dimethylphenyl) acetamide


Lidocaine BP Impurity C


N-(2,6-Dimethylphenyl) acetamide

Lidocaine BP Impurity D



N-(2,6-Dimethylphenyl)-2- (ethylamino) acetamide HCl

Lidocaine BP Impurity F / Lidocaine 2,3-Dimethyl Analog



2-(Diethylamino)-N-(2,3- dimethyl phenyl) acetamide

Lidocaine BP Impurity G


N-(2,6-Dimethylphenyl)-2-[(1- methylethyl)amino]acetamide HC


Lidocaine BP Impurity I / Lidocaine 2,4-Dimethyl Analog



2-(Diethylamino)-N-(2,4- dimethylphenyl)acetamide


Lidocaine BP Impurity K / N- Desethyl-N-Methyl Lidocaine HCl



N-(2,6-Dimethylphenyl)-2- (ethylmethylamino)acetamid
Quetiapine Impurities


Quetiapine EP Impurity D / Quetiapine Dimer


11,11-(1,4-Piperazinediyl)bis- dibenzo[b,f][1,4]thiazepine;

Quetiapine EP Impurity B / Quetiapine Related Compound B


11-(Piperazin-1-yl)dibenzo[b,f] [1,4]thiazepine dihydrochloride


Quetiapine EP Impurity P


11-(4-Ethyl-1-piperazinyl)- dibenzo [b,f][1,4]thiazepine Dihydrochloride





Quetiapine EP Impurity T



11-Morpholino- dibenzo[b,f][1,4] thiazepine hydrochloride



Quetiapine EP Impurity G



dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one




Quetiapine Desethoxy Impurity / Quetiapine EP Impurity I



2-(4-
(dibenzo[b,f][1,4]thiazepin- 11-yl)piperazin-1-yl)ethanol hemifumarate
Cetirizine Impurities



VL330010

Cetirizine 4-chlorobenzhydrol Impurity / Meclizine USP Related Compound A



Cetirizine 4-chlorobenzhyrole




VL330011


Cetirizine 4- chlorobenzophenone Impurity



(4-Chlorophenyl) phenylmethanone



Cinacalcet Impurities




VL2310013


Cinacalcet Phenyl Isomer Impurity



(R)-N-(1-(naphthalen-1- yl)ethyl)-3-phenylpropan-1- amine




VL2310023



Cinacalcet 6-Ethanamine Impurity




1-(Naphthalen-6- yl)Ethanamine




VL2310027



Cinacalcet 6-Ethanone Impurity




1-(Naphthalen-6-yl)Ethanone




VL2310020



Cinacalcet 6-Ethanol Impurity




1-(Naphthalen-6-yl)Ethanol




VL2310037



Cinacalcet Impurity I




(E)-3-(3-
(trifluoromethyl)phenyl) acrylic acid




VL2310013


Cinacalcet Phenyl Isomer Impurity




(R)-N-(1-(naphthalen-1- yl)ethyl)-3-phenylpropan-1- amine
Venlafaxine Impurities




VL286005



Venlafaxine EP Impurity C


1-[2-Amino-1-(4-
methoxyphenyl) ethyl]cyclohexanol Hydrochloride


Darifenacin Impurities



VL1530004


Darifenacin Bromo impurity



5-(2-Bromoethyl)-2,3- dihydrobenzo [2,3-b]furan




VL1530005


Darifenacin Cyano Pyrrolidine Impurity


(S)-3-(Cyanodiphenylmethyl)- pyrro lidine HBr/(3S)-α,α- Diphenyl-3- pyrrolidineacetonitrile Hydrochloride
Trazodone Impurities





VL620006



Trazodone Impurity F / Trazodone Related Compound F




1-(3-chlorophenyl)-4-(3-chloro propyl)piperazine hydrochloride




VL620015


3-chlorophenyl piperazine HCl salt



1-(3-Chlorophenyl)piperazine Hydrochloride
Nicotinamide Impurities




VL2180005


Nicotinamide Impurity A / Nicotinic Acid



3-Pyridinecarboxylic Acid/3- Carboxylpyridine/Niacin




VL2180001


Nicotinamide Impurity B / 3- pyridin ecarbonitrile / Nicotinonitrile



3-Azabenzonitrile/3- Cyanopyridine




VL2180002


Nicotinamide Impurity C / Picolinamide



2-Pyridinecarboxamide/2- Carbamoylpyridine






VL2180003


Nicotinamide Impurity D / Isonicotinamide



4-Pyridinecarboxamide/4- (Aminocarbonyl)pyridine




VL2180004



Nicotinamide Impurity E / Nicotinamide N-Oxide




1-Oxide 3- Pyridinecarboxamide
Albendazole Impurities



VL960001

Albendazole EP Impurity A / Albendazole Amine

5-(Propylsulphanyl) -1H- benzimidazol-2-amine; Desmethoxycarbonyl Albendazole



VL960002


Albendazole EP Impurity B / Sulfoxide


Methyl[5-Propylsulphonyl)- 1H-benzimidazol-2- yl]carbamate; Albendazole Oxide



VL960003


Albendazole Impurity C / Albendazole Sulfone


Methyl[5-Propylsulphonyl)- 1H-benzimidazol-2- yl]carbamate



VL960004


Albendazole EP Impurity D



5-(Propylsulphonyl)- 1Hbenzimidazol-2-amine
Ondansetron Impurities




VL1580001



Ondansetron EP Impurity D



9-Methyl-3-methylene- 1,2,3,9-tetrahydro-4H- carbazol-4-one



VL1580004


Ondansetron EP Impurity H


(3RS)-3-[(2-Methyl-1H-
imidazol-1-yl)methyl]-1,2,3,9- tetrahydro-4H-carbazol-4-one


Bupropion Impurities




VL25004



Chloropropionophenone



3-chloropropiophenone OR 1-
(3-
Chlorophenyl)propan-1-one



VL25014


Bupropion Related Compound C



1-(3-Chlorophenyl)-2-hydroxy- 1-propanone
Olanzapine Impurities




VL109003



Olanzapine Impurity C



1(Chloromethyl) 1methyl4 (2methyl 10Hthieno[2,b][1,5] benzodiazepin-4-yl)- piperazinium Chloride




VL109001


Olanzapine Impurity A / Olanzapine Related Compound A



5-Methyl-2-((2-nitro phenyl)amino)-3- thiophenecarbonitrile



VL109005


Olanzapine Related Compound 07



2-Amino-5-methyl-thiophene- 3-carbonitrile
Clonidine Impurities




VL281001


Clonidine 2,6-dichloroaniline Impurity




2,6-dichloroaniline




VL281004


2,6 dichlorophenyl carbonimidic dichloride / Clonidine Impurity II



2,6 dichloro phenyl carbonimidic dichloride







VL281002



N-(2,6-dichlorophenyl) formamide




N-(2,6-dichlorophenyl) formamide
Diclofenac Impurities




VL48018



Diclofenac Oxindole Impurity
/ Diclofenac EP Impurity E




1,3-Dihydro-2H-indol-2-one



VL48005


Diclofenac Impurity F

N-Chloroacetyl-(2,6- dichlorophenyl) phenylamine OR (Alpha-(2,6-
Dichlorophenyl)-4- chloroacetanilide)
Omeprazole Impurities



VL112002

Omeprazole Related Compound B / Omeprazole Impurity A



5-methoxy-1H-benzimidazole- 2-thiol



VL112010


Omeprazole Impurity XI


2-Chloromethyl-3,5dimethyl- 4-methoxypyridine Hydrochloride
Fingolimod Impurities


VL1270005

Fingolimod Palmitate Amide

N-(1-Hydroxy-2- (hydroxymethyl)-4-(4- octylphenyl)butan-2- yl)palmitamide



VL1270013


Fingolimod Impurity 7


2-Nitro-2-[2-(4-
octylphenyl)ethyl]-1,3- propanediol


VL1270014

Fingolimod Impurity 12

β-Amino-4- octylbenzenebutanol Hydrochloride


Propafenone Impurities



VL260003


Propafenone EP Impurity C



2'-(Oxiranylmethoxy) -3- phenylpropiophenon



VL260005


Propafenone EP Impurity E


DepropylaMino Chloro Propafenone; 1-[2-(3-Chloro- 2-hydroxypropoxy)phenyl]-3- phenyl-1-propanone
Propranolol Impurities




VL188002



Propranolol Diol Derivative



(2RS)-3-(naphthalen-1- yloxy)propane-1,2-diol




VL188001



Propranolol Epoxide Impurity



2-((naphthalen-1- yloxy)methyl)oxirane
Chlorpromazine Impurities




VL2300003



Chlorpromazine EP Impurity E



Perphenazine 2- Chlorophenothiazine Impurity
Nadolol Impurities



VL1380006


Nadolol EP Impurity F


(2RS)-1-[(1,1-Dimethylethyl) amino] -3-(naphthalen-1- yloxy)propan-2-ol
Rufinamide Impurities




VL3000001


Rufinamide Impurity 6 / USP Rufinamide Related Compound A



1-[(2-Fluorophenyl)methyl]- 1H-1,2,3-triazole-4- carboxamide






VL3000002


Rufinamide Related Compound B



Methyl 1-(2,6-Difluorobenzyl)- 1H-1,2,3-triazole-4- carboxylate



VL3000003


Rufinamide Impurity 1 / 2,6- Didesfluoro Rufinamide



1-(Phenylmethyl)-1H-1,2,3- triazole-4-carboxamide












Fenofibrate Impurities
VL59001 Fenofibrate EP Impurity A (4-chlorophenyl)(4-hydroxy phenyl)methanone
VL59002 Fenofibrate EP Impurity B 2-[4-(4-chlorobenzoyl)phenoxy]-2- methylpropanoic acid
VL59003 Fenofibrate EP Impurity C (3RS)-3-[4-(4-chlorobenzoyl) phenoxy]butan-2-one
VL59004 Fenofibrate EP Impurity D Methyl 2-[4-(4-chlorobenzoyl) phenoxy]- 2-methylpropanoate
VL59005 Fenofibrate EP Impurity E Ethyl 2-[4-(4-chlorobenzoyl) phenoxy]-2- methylpropanoate
VL59006 Fenofibrate EP Impurity F (4-Chlorophenyl)[4-(1- methylethoxy)phenyl]methanone

VL59007
Fenofibrate EP Impurity G 1-methylethyl2-[[2-[4-(4-chloro benzoyl)phenoxy ]-2-methyl propanoyl]oxy]-2-methyl propanoate
Lamotrigine Impurities

VL980007 Lamotrigine Impurity B / E-Isomer of Iminoguanidine For Lamotrigine 2-Cyano-2-[(3,4-dichlorophenyl) hydrazono]acetamide
VL980010 Lamotrigine EP Impurity E 2,3-Dichlorobenzoic acid
VL980008 Lamotrigine EP Impurity D / Dioxo Lamotrigine 6-(2,3-Dichlorophenyl)-1,2,4-triazine- 3,5(2H,4H)-dione; Dioxo Lamotrigine
VL980010 Lamotrigine EP Impurity E 2,3-Dichlorobenzoic acid
VL980011 2,3-Dichlorobenzoyl Cyanide Lamotrigine 2,3-Dichlorobenzoyl Nitrile
VL980012 Lamotrigine Impurity / N2- Methyllamotrigine 6-(2,3-dichlorophenyl)-3-imino-2- methyl-1,2,4-triazin-5-amine

VL980013
Lamotrigine Impurity N,N-[6-(2,3-Dichlorophenyl)-1,2,4- triazine-3,5-diyl]bis[2,3- Dichlorobenzamide
VL980015 Lamotrigine Impurity / 3,5- Dichlorobenzoyl Cyanide 3,5-Dichlorophenyl(oxo)acetonitrile
VL980016 Lamotrigine Impurity 6-(3,5-Dichlorophenyl)-1,2,4-triazine-3,5- diamine
VL980017 Lamotrigine Impurity 6-(3,4-Dichlorophenyl)-1,2,4-triazine-3,5- diamine

Metoprolol Impurities
VL103004 Metoprolol Related Compound B (+/-)1-chloro-2-hydroxy-3-[4-(2- methoxyethyl)phenoxy]-propane
VL103015 Metoprolol Epoxide Impurity 1-[2-(2-Methoxyethyl)phenyoxy]-2,3- epoxypropane
Aceclofenac Impurities
VL284007 Aceclofenac Impurity A / Diclofenac Sodium 2-(2-(2,6-dichlorophenylamino) phenyl) sodium acetate
VL284005 Aceclofenac Impurity B / Diclofenac Methyl Ester Methyl [2-[(2,6-dichlorophenyl) amino]phenyl]acetate
VL284006 Aceclofenac Impurity C Ethyl [2-[(2,6-dichlorophenyl)amino] phenyl]acetate
VL284002 Aceclofenac Impurity D Dichlorophenyl)amino]benzeneacetic Acid 2-Methoxy-2-oxoethyl Ester

VL284003
Aceclofenac Impurity E 2-[(2,6-Dichlorophenyl)amino] benzene aceticAcid 2-Ethoxy-2-oxoethyl Ester

VL284001
Aceclofenac Impurity F 2-[(2,6-Dichlorophenyl) amino] benzene acetic Acid 2-Oxo-2-(phenyl methoxy) ethyl Ester
VL284004 Aceclofenac Impurity I 1-(2,6-Dichlorophenyl)-1,3-dihydro-2H- indol-2-one
Paracetamol Impurities
VL2170006 Paracetamol Impurity A N-(2-hydroxyphenyl)acetamide
VL2170005 Paracetamol Impurity B N-(4-hydroxyphenyl)propanamide
VL2170007 Paracetamol EP Impurity D Acetylaniline; N-Phenylacetamide; N- phenylcetamide ; Acetanilide
VL2170008 Paracetamol EP Impurity E 1-(4-hydroxyphenyl)ethan-1-one; 4- Hydroxyacetophenone
VL2170003 Paracetamol EP Impurity F p-Nitrophenol; 1-Hydroxy-4- nitrobenzene
VL2170004 Paracetamol EP Impurity G 4-[1-(hydroxyamino)ethylidene] cyclohexa-2,5-dien-1- one
VL2170009 Paracetamol EP Impurity H N-[4-(Acetyloxy)phenyl]acetamide
VL2170010 Paracetamol EP Impurity I 1-(2-hydroxyphenyl)ethan-1-one
VL2170002 Paracetamol EP Impurity J N-(4-Chlorophenyl)acetamide
VL2170001 Paracetamol EP Impurity K p-Aminophenol; 1-Amino-4- hydroxybenzene
Acetazolamide Impurities
VL11003 Acetazolamide EP Impurity B N-(1,3,4-thiadiazol-2-yl)acetamide
VL11005 Acetazolamide EP Impurity D 2-Amino-1,3,4 thiadiazole-5-Sulfonamide

VL11007
Acetazolamide EP Impurity F N-[5-[(5-Acetamido-1,3,4-thiadiazol-2- yl)sulfonyl]sulfamoyl-1,3,4-thiadiazol-2- yl]acetamide
Aripiprazole Impurities
VL197010 Aripiprazole Impurity A 7-Hydroxy-3,4-dihydroquinolin-2(1H)- one

VL197007 Aripiprazole USP Related Compound G / Aripiprazole EP Impurity E / Dehydro Aripiprazole
7-[4-[4-(2,3-Dichlorophenyl)-1- piperazinyl]butoxy]-2(1H)-Quinolinone

VL197009
Aripiprazole Impurity D 7-[4-[4-(3-Chlorophenyl)-1- piperazinyl]butoxy]-3,4-dihydro-2(1H)- quinolinone
VL197011 Aripiprazole Diquinoline Butanediol Impurity (USP) 1,4-bis[(3,4-Dihydro-2(1H)-quinolinone- 7-yl)oxy]-butane


Carvedilol Impurities
VL35002 Carvedilol Related Compound D 4-(2,3-Epoxypropoxy)carbazole

VL35003
Carvedilol EP Impurity C (2RS)-1-[Benzyl[2-(2-
methoxyphenoxy)ethyl] amino]-3-(9H- carbazol-4- yloxy)propan-2-ol
Atenolol Impurities

VL500008
Atenolol EP Impurity E 2,2-[2-Hydroxypropan-1,3-diylbis(oxy- 4,1-phenylene)]diacetamide

VL500012 Atenolol EP Impurity H / Atenolol USP Related Compound B 2-[4-[(2RS)-2-hydroxy-3-[(1-
methylethyl)amino]propoxy]phenyl]acet onitrile
VL500007 Atenolol EP Impurity D 2-[4-[(2RS)-3-chloro-2-
hydroxypropoxy]phenyl]acetamide


List of all Levothyroxine Impurities

STRUCTURE CHEMICAL NAME M.F. / M. WT. LEAD TIME

Levothyroxine EP Impurity A (2S)-2-Amino-3-[4-(4-hydroxy-3- iodophenoxy)-3,5- diiodophenyl]propanoic acid Chemical Formula: C15H12I3NO4
Molecular Weight: 650.97

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine EP Impurity B (2S)-2-Amino-3-[4-(3-chloro-4- hydroxy-5-iodophenoxy)-3,5- diiodophenyl] propanoic acid Chemical Formula: C15H11ClI3NO4
Molecular Weight: 685.42

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine EP Impurity C
[4-(4-Hydroxy-3-iodophenoxy)-3,5- diiodophenyl]acetic acid Chemical Formula: C14H9I3O4
Molecular Weight: 621.93
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.
Levothyroxine EP Impurity D
[4-(4-Hydroxy-3,5-diiodophenoxy)- 3,5-diiodophenyl]acetic acid Chemical Formula: C14H9I3O4
Molecular Weight: 621.93
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

Levothyroxine EP Impurity E
(2S)-2-Amino-3-[4-(4-
hydroxyphenoxy)-3,5-diiodophenyl]- propanoic acid Chemical Formula: C15H13I2NO4
Molecular Weight: 525.08
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

Levothyroxine EP Impurity F
(2S)-2-Amino-3-[4-[4-(4-hydroxy-3,5- diiodophenoxy)-3,5-diiodophenoxy]- 3,5-diiodophenyl]propanoic acid Chemical Formula: C21H13I6NO5
Molecular Weight: 1120.76
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.
Levothyroxine EP Impurity H
4-(4-Hydroxy-3,5-diiodophenoxy)- 3,5-diiodobenzoic acid Chemical Formula: C13H6I4O4
Molecular Weight: 733.80
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

Levothyroxine EP Impurity I
4-(4-Hydroxy-3,5-diiodophenoxy)- 3,5-diiodobenzaldehyde Chemical Formula: C13H6I4O3
Molecular Weight: 717.80

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine EP Impurity J (2S)-2-Amino-3-[4-(4-hydroxy-3- iodophenoxy)-3-iodophenyl] propanoic acid Chemical Formula: C15H13I2NO4
Molecular Weight: 525.08
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine EP Impurity K
(2S)-2-Amino-3-[4-(4-hydroxy-3,5- diiodophenoxy)-3-iodophenyl] propanoic acid Chemical Formula: C15H12I3NO4
Molecular Weight: 650.97
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.
Levothyroxine Ethyl Ester Impurity Ethyl 2-amino-3-(4-(4-hydroxy-3,5- diiodophenoxy)-3,5-diiodo phenyl) propanoate Chemical Formula: C17H15I4NO4
Molecular Weight: 804.92
More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.



Levothyroxine Methyl Ester Impurity
Methyl 2-amino-3-(4-(4-hydroxy-3,5- diiodophenoxy)-3,5-diiodo phenyl) propanoate Chemical Formula: C16H13I4NO4
Molecular Weight: 790.90

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine N-Acetyl Impurity
N-Acetyl-O-(4-hydroxy-3,5- diiodophenyl)-3,5-diiodo-L-tyrosine Chemical Formula: C17H13I4NO5
Molecular Weight: 818.91

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

Levothyroxine N-Formyl Impurity (S)-2-Amino-3-[4-(4-hydroxy-3,5- diiodophenoxy)-3,5-diiodophenyl]- N-methylpropanamide Chemical Formula: C16H14I4N2O3
Molecular Weight: 789.91

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


Levothyroxine Amide Impurity
2-(4-(4-Hydroxy-3,5-diiodophenoxy)- 3,5-diiodophenyl)acetamide Chemical Formula: C14H9I4NO3
Molecular Weight: 746.84

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

Levothyroxine T4 Hydroxy Acetic Acid Impurity
2-Hydroxy-2-(4-(4-hydroxy-3,5- diiodophenoxy)-3,5- diiodophenyl)acetic acid Chemical Formula: C14H8I4O5
Molecular Weight: 763.83

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.


3,5,3,5-Tetraiodo Thyrolactic Acid Impurity
2-hydroxy-3-(4-(4-hydroxy-3,5- diiodophenoxy)-3,5- diiodophenyl)propanoic acid Chemical Formula: C15H10I4O5
Molecular Weight: 777.85

More than 1g in stock, COA, HPLC, NMR is ok, hplc 98%+.

2018年3月1日星期四

Biggest Manufacturer Elagolix Sodium(832720-36-2) and Elagolix Sodium Intermediates

GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.

Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.

www.eosmedchem.com

1.

Elagolix Sodium (832720-36-2), HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.


Name: Elagolix sodium 
CAS#: 832720-36-2 (sodium) 
Chemical Formula: C32H29F5N3NaO5 
Molecular Weight: 653.57 
Elemental Analysis: C, 60.85; H, 4.79; F, 15.04; N, 6.65; O, 12.67

Related CAS #: 832720-36-2 (sodium)    
Synonym: NBI56418 Na; NBI-56418; NBI 56418.
IUPAC/Chemical Name: Sodium (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)amino)butanoate
InChi Key: FLFGNMFWNBOBGE-FNNZEKJRSA-N
InChi Code: InChI=1S/C27H45N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(31)35-20-21-24(32)25(33)26(36-21)30-19-18-22(28)29-27(30)34/h9-10,18-19,21,24-26,32-33H,2-8,11-17,20H2,1H3,(H2,28,29,34)/b10-9+/t21-,24-,25+,26-/m1/s1
SMILES Code: O=C([O-])CCCN[C@H](C1=CC=CC=C1)CN(C(N(CC2=C(C(F)(F)F)C=CC=C2F)C(C)=C3C4=CC=CC(OC)=C4F)=O)C3=O.[Na+]

2.

Elagolix Sodium intermediate

Elagolix Sodium intermediate 5(830346-46-8), 

HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Elagolix Sodium intermediate 6(830346-47-9),

HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Elagolix Sodium intermediate 7-1(1150560-54-5),

HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Elagolix Sodium intermediate 7-2(830346-48-0),

HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.


Elagolix Sodium intermediate 8(1150560-59-0),HPLC 99%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.





REFERENCES
1: Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28. doi: 10.2217/whe.14.68. PubMed PMID: 25581052.
2: Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-51. doi: 10.1177/1933719114549848. Epub 2014 Sep 23. PubMed PMID: 25249568; PubMed Central PMCID: PMC4212335.
3: Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014 Mar;21(3):363-71. doi: 10.1177/1933719113497292. Epub 2013 Jul 24. PubMed PMID: 23885105.
4: Deal watch: Abbott and Neurocrine to develop promising endometriosis drug. Nat Rev Drug Discov. 2010 Aug;9(8):584. doi: 10.1038/nrd3246. PubMed PMID: 20671753.
5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PubMed PMID: 19967103.
6: Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009 Feb;94(2):545-51. doi: 10.1210/jc.2008-1695. Epub 2008 Nov 25. PubMed PMID: 19033369; PubMed Central PMCID: PMC2646513.
7: Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4 -methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85. doi: 10.1021/jm8006454. PubMed PMID: 19006286.

EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China

2018年2月27日星期二

Biggest Manufacturer Trabectedin and Trabectedin Intermediates 96996-50-8, 236743-98-9

GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.

Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.

www.eosmedchem.com

1.

Trabectedin, Cas#114899-77-3, HPLC 99.2%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.

Product Name:ecteinascidin 743
Synonyms:ecteinascidin 743;Trabectedin;(1'R,6R,6aR,7R,13S,14S,16R)-;ET-743;Yondelis;Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis);Ecteinascidin;Ecteinascidine 743
CAS:114899-77-3
MF:C39H43N3O11S
MW:761.845
Mol File:114899-77-3.mol

COA, pls check:

2.

Trabectedin intermediate, Cas# 96996-50-8, HPLC 99.2%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.


CAS:96996-50-8
MF:C29H35N5O6
MW:0
EINECS:
Synonyms:cyanosafracin B;Cyanoquinonamine

Trabectedin intermediate, Cas# 236743-98-9, HPLC 99.2%, NMR, LCMS, MSDS, COA, MOA all we provided, More than 100g in stock.






REFERENCES
1: Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol. 2017 Oct 1;28(10):2559-2566. doi: 10.1093/annonc/mdx357. PubMed PMID: 28961837.
2: Erba E, Romano M, Gobbi M, Zucchetti M, Ferrari M, Matteo C, Panini N, Colmegna B, Caratti G, Porcu L, Fruscio R, Perlangeli MV, Mezzanzanica D, Lorusso D, Raspagliesi F, D'Incalci M. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4. PubMed PMID: 28782526.
3: Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6. PubMed PMID: 28683469; PubMed Central PMCID: PMC5572168.
4: Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20. PubMed PMID: 28105566.
5: Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Invest New Drugs. 2017 Apr;35(2):198-206. doi: 10.1007/s10637-016-0410-3. Epub 2016 Nov 21. PubMed PMID: 27873130.
6: Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3. PubMed PMID: 27697767; PubMed Central PMCID: PMC5567825.
7: Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. Dis Model Mech. 2016 Dec 1;9(12):1461-1471. Epub 2016 Oct 20. PubMed PMID: 27780828; PubMed Central PMCID: PMC5200894.
8: Santamaría Nuñez G, Robles CM, Giraudon C, Martínez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM. Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. Mol Cancer Ther. 2016 Oct;15(10):2399-2412. Epub 2016 Sep 14. PubMed PMID: 27630271.
9: Metaxas Y, Cathomas R, Mark M, von Moos R. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases. Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14. PubMed PMID: 27440191.
10: Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget. 2016 May 3;7(18):25885-901. doi: 10.18632/oncotarget.8292. PubMed PMID: 27029031; PubMed Central PMCID: PMC5041952.
11: Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, Kozasa K, Hashimoto K, Sawada K, Kimura T. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One. 2016 Mar 17;11(3):e0151050. doi: 10.1371/journal.pone.0151050. eCollection 2016. PubMed PMID: 26986199; PubMed Central PMCID: PMC4795692.
12: Pernice T, Bishop AG, Guillen MJ, Cuevas C, Aviles P. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma. J Pharm Biomed Anal. 2016 May 10;123:37-41. doi: 10.1016/j.jpba.2016.01.043. Epub 2016 Jan 21. PubMed PMID: 26871278.
13: Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15;20(8):2205-14. doi: 10.1158/1078-0432.CCR-13-1880. Epub 2014 Feb 21. PubMed PMID: 24563480.
14: Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25. PubMed PMID: 23588839.
15: Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Martí L, Ponce J, Molleví DG, Capella G, Condom E, Viñals F, Huertas D, Cuevas C, Esteller M, Avilés P, Villanueva A. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012 Oct 1;18(19):5399-411. doi: 10.1158/1078-0432.CCR-12-1513. Epub 2012 Aug 15. PubMed PMID: 22896654.

EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China